Introduction
COPD is projected to be the third-leading cause of death worldwide by 2020.
1, 2 COPD is a chronic lung disease characterized by severely impaired normal lung function. The development of COPD appears to occur slowly and progressively over many years, as it is generally diagnosed in middle-aged or older individuals. 2 Exposure to cigarette smoke is a major risk factor for the development of COPD. 3 Only a subset of cigarette smokers develop COPD and other factors such as air pollution and infections also contribute to its pathogenesis suggests that both genetic factors and environmental modifiers contribute to the development of COPD. 4 Although the mechanisms underlying the development and progression of this disease remain enigmatic, histopathologic examination of the lungs of patients with severe COPD has revealed a severe loss of lung tissue, especially of the alveolar type II cells, and persistent lung inflammation (reviewed in). 5 Data obtained from molecular and cellular analyses of lung tissue samples from COPD patients and from experimental mouse models of emphysema have suggested critical roles for deregulated cell proliferation, antioxidant-oxidant imbalance, and apoptosis as well as degradation of the extracellular matrix in COPD. 6 The activator protein 1 (AP-1), comprised of the c-Jun (c-Jun, Jun-B, and Jun-D) and
Fos (Fos, Fos-B, Fra-1, and Fra-2) families of DNA binding proteins, binds to the TPA response element (TRE, TGAC/GTCA) and regulates the expression of genes involved in various biological processes including cell proliferation, differentiation, cell death, inflammation, and cellular defense. 7 Various cellular processes controlled by the AP-1 transcriptional factor have been reported to be deregulated in lung tissue/cell types obtained from COPD patients. 5 Although the members of the AP-1 family of proteins are activated in response to various insults in lung epithelial cells, 8 whether the activation of AP-1 proteins is critical to confer protection on the host or to enhance the host's susceptibility to the development and progression of lung diseases is still largely undefined in vivo. Thus, in the present study, we have examined the role of c-Jun/AP-1 transcription factors in COPD. First, we determined the expression levels of this transcription factor in COPD clinical samples and found the loss of c-Jun expression in the lung tissues obtained from very severe-COPD patients (GOLD stage IV) when compared to control non-COPD individuals. Since conventional deletion of c-Jun results in embryonic lethality, 9 we utilized a mouse model in which c-Jun was specifically deleted in type II alveolar epithelial cells. We then examined the effects of c-Jun deficiency on both lung development and on cigarette smoke-induced lung inflammation and tissue destruction in these mice. Here, we report for the first time that the c-Jun deficiency in alveolar type II epithelial cells results in progressive emphysema and also perpetuates cigarette smoke-induced lung inflammation in vivo.
Materials and Methods
Human lung tissue samples: Lung tissue samples used in this study were obtained from the Lung Tissue Research Consortium funded by the NHLBI. One tissue sample was obtained from each subject; i.e. 'n' represents the number subjects in this study. Patients' lung function data were obtained from established patient registries. The subjects were classified as per severity of COPD according to the guidelines of the Global Initiative for
Obstructive Lung Disease (GOLD). The non-COPD population (21 samples with 15 former smokers, 1 current smoker and 6 never smokers) had normal lung function performance and no evidence of COPD (Table 1) . Groups for COPD lungs included GOLD-II, GOLD-III and GOLD-IV on the basis of lung function tests. Clinical and demographical characters of these patients are presented in Table 1 .
Mice:
Mice carrying the floxed c-Jun allele (hereafter referred to as c-Jun f/f ) were generated on C57BL/6x129SVJ background as described elsewhere. 10 Mice expressing
Cre recombinase under the control of SP-C promoter on C57BL/6 background were obtained from Dr. Brigid Hogan, Duke University. 11 Wild type mice with C57BL6x129SVJ background were used as additional controls in selective experiments.
To All animal protocols were performed in accordance with guidelines approved by the animal care and use committee at the Johns Hopkins University.
PCR genotyping and determination c-Jun deletion in alveolar epithelial cells:
We and Cre: ACGAACCTGGTCGAAATC AGTGCG (reverse) primers were used as outlined ("see Supplemental Figure S1B at http://ajp.amjpathol.org"). Alveolar type II epithelial cells were isolated and cultured as described previously. 12 For the detection of c-Jun deletion in lung epithelium, the genomic DNA from type II epithelial cells was amplified using Jun1 and Jun3 (CAGGGCGTTGTGTCA CTGAGCT, reverse) primers ("see Supplemental Diagram S1B at http://ajp.amjpathol.org").
Cigarette smoke exposure: Mice (8-week old) were divided into two groups: control and cigarette smoke exposure groups. Control groups were housed in a filtered air environment. Experimental groups were subjected to cigarette smoke exposure for 5 6 h/day, 5 days/week for 6 months using whole-body smoke exposure system (Model The blots were developed with the ECL Western blot detection system (Thermo Scientific, Rockford, IL). Bands were quantified using β-actin as reference. COPD to non-COPD control samples, our main comparison, using linear regression models without any adjustment and with further adjustment for sex, age and cigarette pack-years. We also used Bonferroni correction for multiple comparisons.
Immunohistochemistry
All animal data were expressed as the mean ± SEM (n = 8 for each condition). One-way ANOVA followed by Newman-Kuels post hoc analysis was performed for multiple comparisons. P values with < 0.05 were considered as statistically significant. For comparing the interaction between age and emphysema, two-way ANOVA with a Bonferroni correction was used. A Bonferroni-corrected P value of < 0.05 was used to identify statistical significance.
RESULTS

Deregulation of c-JUN expression in COPD lung tissues
To Histopathologic examination revealed the lymphocyte infiltrates adjacent to the blood vessels and airways in the lungs of c-Jun ∆ae mice exposed to cigarette smoke ( Figure 5B ; "See Supplemental Figure S4 for 40x images at http://ajp.amjpathol.org") that resembled the bronchus associated lymphoid tissue (BALT) phenotype observed in the lung tissue of COPD patients. 22 We then used morphometry to quantify the effects of c-Jun deficiency on lung tissue destruction. As expected, the MCL in lungs of cigarette smoke-exposed c-Jun f/f mice was greater than that in the filtered room air-exposed control group ( Figure 5C ).
However, cigarette smoke exposure did not alter the magnitude of emphysema caused by the deletion of c-Jun ( Figure 5C ). The average MCLs of cigarette smoke-exposed c-Jun ∆ae mice were comparable to those of room air-exposed c-Jun ∆ae mice. These results strongly support a prominent role for c-Jun in the proper maintenance of lung alveolar cell homeostasis and in reducing the lung inflammation induced by cigarette smoke.
We further identified the cell types infiltrating the perivascular and peribronchiolar regions of the lungs of c-Jun mutant mice by immunostaining the lung tissue sections with the anti-CD3
and anti-B220 antibodies, which specifically stain T-lymphocytes and B-lymphocytes, respectively. Immunostaining revealed that the perivascular and peribronchial infiltrates in the lungs of c-Jun ∆ae mice consisted mainly of T-( Figure 5D ) and B-lymphocytes ( Figure   5E ). This type of immune infiltration was not seen in the lungs of cigarette smoke-exposed cJun f/f mice or in the lungs of filter air-exposed control mice of either genotype. Importantly, the lack of the c-Jun transcription factor enhanced the severity of cigarette smoke-induced lung inflammation with lymphocyte infiltrates, which are observed in the lungs of COPD patients. 22 In contrast, a specific deletion of c-Jun in Clara cells did not cause progressive emphysema in mice data not shown) nor was any such phenotype detectable in wild-type mice with Cre recombinase at up to 12 months of age ("See Supplemental Figure S3 at http://ajp.amjpathol.org"). Thus, it appears that a loss of c-Jun expression specifically in the alveolar epithelium may enhance susceptibility to the development and progression of emphysema.
DISCUSSION
COPD is characterized by chronic bronchitis and emphysema. Various experimental models of emphysema have been used to elucidate the mechanisms underlying the pathogenesis of COPD. One of these models, cigarette smoke, has been widely used because it utilizes the relevant etiological agent that causes COPD. We and others have shown that chronic exposure to cigarette smoke in the mouse displays several of the characteristic hallmarks of COPD, including airspace enlargement, oxidative stress, apoptosis, inflammation, and protease-anti-protease imbalance. 13, 23 One of the limitations of the chronic cigarette smoke model, however, is the mild degree of emphysema it produces. Several studies have utilized other non-smoking models, such as the instillation of elastase, 24, 25 VEGF inhibition, 26, 27 caspase 3 instillation, 28 and ceramide activation. 29 These models have the advantage of causing airspace enlargement in a shorter period of time (cigarette smoke exposure requires 6 months), and they are also known to induce lung inflammation and cellular apoptosis, which lead to airspace enlargement. However, although there are limitations associated with using chronic cigarette smoke exposure in mice (such as a lack of chronic bronchitis because of undetectable levels of mucus production), this model has been considered the most relevant model for COPD research because it uses the etiologic agent that causes the majority of COPD cases.
Both alveolar epithelial and endothelial cell apoptosis and proliferation are known to be deregulated in the lungs of rodents exposed to experimental emphysema, 6 as well as in the lungs of patients with emphysema COPD. 20 This phenotype has been generally attributed to elevated levels of oxidative stress, and protease-anti-protease imbalance caused by the impact of cigarette smoke on lung structural cells and of infiltrated leukocytes. Inflammation is a common feature in the pathogenesis of many chronic conditions, including COPD/emphysema. 21 Multiple cytokines orchestrate the recruitment and activation of inflammatory cells and thereby contribute to both acute and chronic airway diseases such as COPD. 41 In the present study, we found increased levels of a pro-inflammatory cytokine TNFα in BAL fluids obtain from 3-and 8-month-old c-Jun mutant mice as compared to wild type mice. TNFα has been implicated in emphysema. For example, increased levels of TNFα has been observed in COPD patients 42 and in cigarette smoke-induced experimental emphysema. 43 c-Jun has been shown to regulate the TNFα levels through regulating the expression of tissue inhibitor of metalloproteinase 3 (TIMP3), 44 a potent inhibitor of TNFα converting enzyme (TACE). Conditional and inducible deletion of both c-Jun and Jun-B in the epidermis of adult mice developed psoriasis-like inflammatory skin disease. 45 Analysis of skin lesions in these double mutant mice revealed a remarkable increase in the inflammatory cells consisting of T-lymphocytes and inflammatory cytokines such as TNFα, IL12p40, MIP1, and MIP2. 45 We also found increased levels of IL13, Cxcl1, and IL12p40, in c-Jun mutant mice ( Figure 4B ). Lung specific expression of IL13 promoted the development of emphysema and inflammation, 46 whereas Cxcl1 possesses neutrophil chemoattractant activity and IL12p40 regulates immune responses. 47 Thus, it is likely that a deregulated 21 cytokine expression resulting from lack of the c-Jun/AP-1 signaling in the alveolar epithelium contributes to the progression of emphysema.
We noted a persistent presence of foamy (atypical) alveolar macrophages in c-Jun ∆ae mice, which was correlated with the lung tissue damage and progression of emphysema. 
